A AGILENT TECHNOLOGIES, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 1090872 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY18.0%
TTM EPS YoY18.5%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR8.3%
Margins
Gross margin53.8%
Operating margin22.2%
Net margin19.5%
FCF margin17.2%
EBITDA margin25.9%
Returns
ROE21.0%
ROA11.0%
ROIC (approx.)16.0%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets47.3%
Debt / equity0.54x
Current ratio2.05x
Interest coverage15.46x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-1.3%
Payout ratio19.9%
Capex / revenue4.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 | FY20232023-10-31 | FY20222022-10-31 | FY20212021-10-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B |
| Cost of revenue | $3.31B | $2.98B | $3.37B | $3.13B | $2.91B |
| Gross profit | $3.64B | $3.54B | $3.46B | $3.72B | $3.41B |
| R&D expense | $455.00M | $479.00M | $481.00M | $467.00M | $441.00M |
| SG&A expense | $1.71B | $1.57B | $1.63B | $1.64B | $1.62B |
| Operating income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B |
| Interest expense | $112.00M | $96.00M | $95.00M | $84.00M | $81.00M |
| Pretax income | $1.44B | $1.52B | $1.34B | $1.50B | $1.36B |
| Income tax | $132.00M | $232.00M | $99.00M | $250.00M | $150.00M |
| Net income | $1.30B | $1.29B | $1.24B | $1.25B | $1.21B |
| EBITDA | $1.77B | $1.75B | $1.62B | $1.94B | $1.67B |
| EPS (basic) | 4.59 | 4.44 | 4.22 | 4.19 | 3.98 |
| EPS (diluted) | 4.57 | 4.43 | 4.19 | 4.18 | 3.94 |
| Dividends declared per share | 0.99 | 0.94 | 0.90 | 0.84 | 0.78 |
| Weighted avg. shares (diluted) | 285.00M | 291.00M | 296.00M | 300.00M | 307.00M |
| Balance sheet | |||||
| Cash & equivalents | $1.79B | $1.33B | $1.59B | $1.06B | $1.49B |
| Receivables | $1.49B | $1.32B | $1.29B | $1.41B | $1.17B |
| Inventory | $1.02B | $972.00M | $1.03B | $1.04B | $830.00M |
| Current assets | $4.59B | $3.96B | $4.19B | $3.78B | $3.80B |
| PP&E, net | $2.02B | $1.78B | $1.27B | $1.10B | $945.00M |
| Goodwill | $4.47B | $4.48B | $3.96B | $3.95B | $3.98B |
| Intangibles | $445.00M | $547.00M | $475.00M | $821.00M | $981.00M |
| Total assets | $12.73B | $11.85B | $10.76B | $10.53B | $10.71B |
| Current liabilities | $2.35B | $1.90B | $1.60B | $1.86B | $1.71B |
| Short-term debt | $304.00M | $45.00M | $0 | $36.00M | $0 |
| Long-term debt | $3.05B | $3.35B | $2.73B | $2.73B | $2.73B |
| Total debt | $3.35B | $3.39B | $2.73B | $2.77B | $2.73B |
| Total liabilities | $5.99B | $5.95B | $4.92B | $5.23B | $5.32B |
| Shareholders' equity | $6.74B | $5.90B | $5.84B | $5.30B | $5.39B |
| Net debt | $1.56B | $2.06B | $1.15B | $1.71B | $1.24B |
| Shares outstanding | 283.05M | 285.19M | 292.12M | 295.26M | 302.00M |
| Cash flow statement | |||||
| Operating cash flow | $1.56B | $1.75B | $1.77B | $1.31B | $1.49B |
| Capital expenditure | $407.00M | $378.00M | $298.00M | $291.00M | $188.00M |
| Free cash flow | $1.15B | $1.37B | $1.47B | $1.02B | $1.30B |
| Investing cash flow | -$394.00M | -$1.26B | -$310.00M | -$338.00M | -$749.00M |
| Financing cash flow | -$715.00M | -$752.00M | -$930.00M | -$1.37B | -$696.00M |
| Depreciation & amortization | $288.00M | $257.00M | $271.00M | $317.00M | $321.00M |
| Stock-based compensation | $128.00M | $129.00M | $111.00M | $125.00M | $110.00M |
| Dividends paid | $282.00M | $274.00M | $265.00M | $250.00M | $236.00M |
| Share buybacks | $425.00M | $1.15B | $575.00M | $1.14B | $788.00M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.